NORGESIC FORTE
Clinical safety rating
cautionComprehensive clinical and safety monograph for NORGESIC FORTE (NORGESIC FORTE).
Norgesic Forte is a combination of orphenadrine citrate and aspirin (acetylsalicylic acid). Orphenadrine is a centrally acting muscle relaxant with anticholinergic and antihistaminic properties; it acts via blockade of nicotinic acetylcholine receptors at the neuromuscular junction and centrally as a non-competitive antagonist at NMDA receptors, reducing hypertonicity and spasm. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
| Metabolism | Orphenadrine: extensively hepatic, primarily via N-demethylation (CYP2B6, CYP3A4) and hydroxylation; aspirin: rapidly hydrolyzed to salicylic acid by esterases (liver, plasma, erythrocytes), further metabolized by conjugation with glycine (salicyluric acid) and glucuronic acid, and oxidation to gentisic acid. |
| Excretion | Renal (70% as unchanged drug and conjugates), fecal (20%), biliary (10%) |
| Half-life | Terminal elimination half-life: 4-6 hours; in elderly or hepatic impairment, half-life may be prolonged up to 12 hours, necessitating dose adjustment. |
| Protein binding | 95% bound; primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd: 1.0 L/kg; indicates extensive tissue distribution ( > total body water, 0.6 L/kg). |
| Bioavailability | Oral: 80-90% (due to first-pass metabolism); intramuscular: 100% |
| Onset of Action | Oral: 30-60 minutes; intramuscular: 15-30 minutes |
| Duration of Action | Oral: 4-6 hours; intramuscular: 4-8 hours. Clinical note: Duration may be shorter with acute pain and longer with chronic conditions due to accumulation. |
| Molecular Weight | 305.4 |
1 tablet orally 3 times daily. Each tablet contains orphenadrine citrate 100 mg and paracetamol 500 mg.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in severe renal impairment (CrCl <30 mL/min). For moderate impairment (CrCl 30-60 mL/min), reduce frequency to twice daily. No adjustment for mild impairment. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce dose by 50% or extend interval. Use with caution in mild impairment. |
| Pediatric use | Not recommended for children under 12 years. For adolescents 12-18 years, 1 tablet orally twice daily. |
| Geriatric use | Initiate at 1 tablet orally twice daily due to increased risk of anticholinergic effects and renal clearance decline. Monitor for confusion, urinary retention, and falls. |
| 1st trimester | Contraindicated: orphenadrine has been associated with fetal malformations in animal studies. No adequate human studies. |
| 2nd trimester | Contraindicated: potential risk of fetal harm outweighs benefits. |
| 3rd trimester | Contraindicated: may cause neonatal adverse effects, including anticholinergic symptoms. |
Clinical note
Comprehensive clinical and safety monograph for NORGESIC FORTE (NORGESIC FORTE).
| Placental transfer | Orphenadrine crosses the placenta, as evidenced by animal studies and limited human data. The degree is not well quantified. |
| Breastfeeding | Orphenadrine is excreted into breast milk in small amounts. Since anticholinergic effects may occur in the infant, it is generally not recommended during breastfeeding. If used, monitor infant for anticholinergic symptoms. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | First trimester: Avoid due to potential skeletal and visceral malformations (animal studies). Second/third trimester: Risk of premature closure of ductus arteriosus and oligohydramnios (NSAID component orphenadrine/paracetamol with NSAID? Note: Norgesic Forte contains orphenadrine, paracetamol, and caffeine; no NSAID clinically; teratogenicity primarily from orphenadrine anticholinergic effects). Limited human data; consider alternative. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, urinary retention, and CNS anticholinergic effects. Fetal monitoring: assess amniotic fluid index if prolonged use (potential oligohydramnios from anticholinergic effects on fetal renal function). |
| Fertility Effects | No known specific effects on fertility. Potential anticholinergic impairment of sexual function in males (erectile dysfunction). Paracetamol at high doses may affect ovarian function; caffeine may reduce fertility at high intake. |
■ FDA Black Box Warning
None
| Serious Effects |
GlaucomaObstructive uropathy (e.g., prostatic hypertrophy)Myasthenia gravisSevere cardiac disease (e.g., arrhythmias, congestive heart failure)Hypersensitivity to orphenadrine or any componentConcurrent use of propoxyphene (increased CNS depression)
| Precautions | Anticholinergic effects: confusion, hallucinations, urinary retention, blurred vision; caution in patients with glaucoma, prostatic hypertrophy, or myasthenia gravis; CYP2B6/CYP3A4 interactions; aspirin-related: increased bleeding risk, Reye's syndrome in children/viral illness, salicylate toxicity; avoid use with alcohol, other NSAIDs, or anticoagulants; use with caution in renal impairment, hepatic impairment, or peptic ulcer disease; may cause drowsiness or dizziness. |
| Food/Dietary | Avoid alcohol. Take with food to minimize GI irritation. Caffeine content (30 mg per tablet) may cause jitteriness if combined with other caffeine sources. High-tyramine foods (aged cheese, cured meats) may increase pressor effect in susceptible individuals, though less common with this combination. |
| Clinical Pearls | Norgesic Forte combines orphenadrine citrate (muscle relaxant) with aspirin and caffeine. Avoid in glaucoma, myasthenia gravis, and GI obstruction. Monitor for anticholinergic effects (dry mouth, blurred vision, urinary retention). Use with caution in elderly due to risk of confusion and falls. Not recommended for long-term use beyond 2-3 weeks. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause dizziness, drowsiness, or blurred vision. · Avoid alcohol and other CNS depressants. · Report severe stomach pain, black stools, or vision changes immediately. · Do not take more than prescribed; overdose can cause serious cardiac effects. |
Loading safety data…